Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Location
One Main Street, Suite 1350, Cambridge, MA
Fiscal year end
December 31
Former names
Cullinan Oncology, Inc. (to 4/2/2024), Cullinan Management, Inc. (to 2/22/2021), Cullinan Oncology, LLC (to 1/6/2021)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.15K % +4.81%
Debt-to-equity 5.24 % +1.16%
Return On Equity -28.4 % -5.39%
Return On Assets -27 % -5.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58M shares +35.7%
Common Stock, Shares, Outstanding 57.9M shares +35.4%
Entity Public Float 374M USD -0.4%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 55.1M shares +37.8%
Weighted Average Number of Shares Outstanding, Diluted 55.1M shares +37.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 136M USD +12.5%
General and Administrative Expense 47.7M USD +13%
Operating Income (Loss) -184M USD -12.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -212%
Income Tax Expense (Benefit) -14.1M USD -134%
Net Income (Loss) Attributable to Parent -142M USD -0.28%
Earnings Per Share, Basic -3.06 USD/shares +10.3%
Earnings Per Share, Diluted -3.06 USD/shares +8.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115M USD -18.9%
Other Assets, Current 3.9M USD
Assets, Current 678M USD +36%
Other Long-term Investments 15.5M USD -49.5%
Property, Plant and Equipment, Net 836K USD -27.8%
Operating Lease, Right-of-Use Asset 2.12M USD -39.4%
Other Assets, Noncurrent 460K USD +0.22%
Assets 681M USD +30.5%
Accounts Payable, Current 1.56M USD -37.6%
Accrued Liabilities, Current 20.7M USD +33.3%
Liabilities, Current 23.5M USD +19.3%
Operating Lease, Liability, Noncurrent 1.52M USD -44.4%
Liabilities 25M USD +11.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -476K USD +70.7%
Retained Earnings (Accumulated Deficit) -280M USD -103%
Stockholders' Equity Attributable to Parent 656M USD +31.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 656M USD +31.4%
Liabilities and Equity 681M USD +30.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +25%
Net Cash Provided by (Used in) Financing Activities 1.09M USD -39.4%
Net Cash Provided by (Used in) Investing Activities 13M USD -14.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 57.9M shares +35.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 87.4M USD +86.8%
Deferred Tax Assets, Gross 88.3M USD +83.3%
Operating Lease, Liability 2.73M USD -37.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -141M USD -0.9%
Lessee, Operating Lease, Liability, to be Paid 3.05M USD -40%
Property, Plant and Equipment, Gross 1.34M USD +2.45%
Operating Lease, Liability, Current 1.22M USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 871K USD -40.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD -15.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 312K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 14.4M USD +37.1%
Preferred Stock, Shares Issued 648K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 872K USD
Preferred Stock, Shares Outstanding 648K shares 0%
Depreciation, Depletion and Amortization 76K USD +5.56%
Deferred Tax Assets, Net of Valuation Allowance 914K USD -34.8%
Share-based Payment Arrangement, Expense 34M USD +21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%